Dr. David Samadi’s Career in Medicine and Robotic Surgery

David Samadi is one of the most respected professionals in the medical field. Currently serving as the Chief of Robotic Surgery at Lenox Hill Hospital, Dr. Samadi is an Iranian-born doctor. He grew up in Persia until the Iranian Revolution. He was sent to Belgium together with his brother, but they ended up growing up without their parents.

Early Childhood and Background

Right from an early age, Dr. Samadi knew that he wanted to help others. His dream of becoming a doctor was conceived at that stage in life. His main goal while growing up was to help people to fight cancer. With his passion, he worked towards this goal, and he ended up studying medicine and surgery. He is a graduate from the Stony Brook School of Medicine. He also did his post-graduate training at Montefiore Medical Center as well as the Albert Einstein College of Medicine.

With his training in medicine, Dr. David Samadi is dedicated to diagnosing and treating prostate cancer. He is also keen on sharing his knowledge with others through TV and radio shows. Dr. David Samadi also has a website where he discusses issues to do with men’s health. His other interests in the field of medicine include newer treatment technologies and alternative medicine.

David Samadi’s Robotic Method

When asked how he manages to make money with his business, Dr. David Samadi refers to his robotic method of treating prostate cancer. He developed the robotic method to provide less invasive surgical options for men. The unique method has helped many men deal with their health issues, and preventing them from contracting various types of cancers.

His knowledge of cancer diagnostics and treatment was also informed by working in different parts of the world. Dr. David Samadi was lucky enough to work in France while starting his career. It was during this time that he helped to create cancer treatment solutions including laparoscopic procedures for men. He continues to help his patients in achieving overall good health. When he is not working, he likes to contribute to charitable activities around him.

Dr. David Samadi Social Media: twitter.com/drdavidsamadi

The Achievements of Oncotarget To Be Seen

Oncotarget was originally initiated in 2010 as a traditional journal with multiple disciplines. One of the main factors that has proceeded to make Oncotarget rather infamous is its dedication to its core value: democratization.

One of the most strongest shows of evidence is the Creative Commons Attribution 3.0 License, this allows people to take the research studies from Oncotarget and share it more easily with others.

Bearing in mind, there are other suggested studies that that Oncotarget has taken a focus towards besides just oncology: other topics of importance are gerotargeting, cell death, autophagy, pathology, immunology, and other topics of related interest.

This democratized approach where research studies can be easily shared allows breakthroughs from Oncotarget to happen much faster than it normally would.

This is perfect because ultimately, this saves time.

Another factor of the democratization approach is that Oncotarget is listed in recognized scientific indexes.

Oncotarget is constantly staying up-to-current-affairs by archiving published experiments each and every day. Check Oncotarget at scimagojr.com

The free and open access is a core value that Oncotarget takes rather seriously.

Moving Forward in the Media Landscape

Oncotarget proceeds with its stated objectives in regards to its media platform.

In fact, earlier in 2017, Oncotarget had stated that their goal was to transform the journal altogether into a twice-weekly publication.

One notable achievement has been reached.

The end result with the notable increase the frequency of their publication is the media consumers won’t have to worry about hiatuses.

The following achievement is that Oncotarget has created its own podcast. The overall purpose of that podcast is to detail its findings in podcasting format.

People will be able to listen to accomplishments and the breakthroughs that have been done and documented in Oncotarget.

The podcast can be listened to on podcasting platforms such as Stitcher, Soundcloud, Player.FM, and iTunes.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

What Are Other Achievements that Oncotarget Made?

Oncotarget has been involved with current achievements, as well.

Oncotarget has been able to share that a few Oncotarget researchers have been able to identify new therapeutic strategies to treat thyroid cancer.

Oncotarget still has remained indexed by most scientific databases such as Biological Abstracts, Embase, BIOSIS Previews, and Scopus.

Oncotarget’s accomplishments should defintely be acclaimed.

The Concept of Democratization

Due to the democratized nature of the journal, Oncotarget has allowed for its researched and published experiments to be shared much more easily and more expediently. Watch this video on Youtube.

Democratization is a cause and a core value that Oncotarget heavily abides by.

Changing Cancer Treatment Therapies through ADCs-Clay Siegall and Seattle Genetics

Dr. Clay Siegall is the co-founder of Seattle Genetics. The company was founded in 1998 and has been the president and CEO since 2002. He also serves as the chairman of the board of directors. He then worked with the National Cancer Institute, National Institute of Health (1988-1991). Before Seattle Genetics, Dr. Siegall used to work for Bristol-Myers Squibb Pharmaceutical Research Institute (1991-1997).

Dr. Siegall was affected by cancer early on in life when his father was diagnosed with it. He was only 19 at the time, and this became his driving force to be what he is today. His father passed on when he was 24. His only goal in the world is to provide better treatment for cancer patients. He has been doing this for the last 30 years and has no intention of stopping soon. His advice to young entrepreneurs is to interact with smart people who have expertise and experience and learn as much as you can.

Seattle Genetics was founded with a vision of developing innovative biotechnological research with the aim of helping patients. The company has several licenses including with Pfizer. Under the leadership of Dr. Siegall, the company has generated more than $1.2 billion through public and private funding. The funding has allowed the company to continue to be a trailblazer in advancing cancer treatment through innovative technology. His scientific mind and visionary leadership make him a very rare type of individual. He is propelling not only his company but the entire industry to new heights. Under Dr. Siegall the company has entered into multiple strategic licenses for their ADC technology, which has, in turn, made them industry leaders in the field of antibody-drug conjugates. With the FDA approval of the companies’ first ADC product, ADCENTRIS the company has generated more than $350 million to date. With the drug now approved in more than 65 countries.

Dr.Siegall holds a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He has more than 70 publications on his resume and holds 15 patents. Dr.Siegall has received several awards. In 2012 he was awarded Pacific Northwest Ernst & Young Entrepreneur of the Year and in 2013 the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences.